No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men

Abstract

SUMMARYThe relationship between androgen deprivation therapy (ADT) and coronary heart disease (CHD) remains controversial. Furthermore, the majority of such studies focused on Caucasian populations, and there is still a paucity of studies among Asian populations. This population-based study aimed to investigate the relationship between ADT and CHD in an ethnic Chinese (i.e., Taiwanese) population. We used data sourced from the Taiwan 'Longitudinal Health Insurance Database'. This study included 1278 patients with prostate cancer in the study group and 1278 subjects without prostate cancer in the comparison group. Each patient was individually tracked for a 3-year period to identify those who had subsequently received a diagnosis of CHD. The results showed that the incidence rate of CHD during the 3-year follow-up period was 4.69 (95% CI: 2.99-5.48) per 100 person-years and 2.67 (95% CI: 2.15-3.27) per 100 person-years for the study and comparison cohort, respectively. The Cox proportional hazard regression showed that the hazard ratio for CHD during the 3-year follow-up period for prostate cancer patients was 1.65 (95% confidence interval (CI) = 1.25-2.16) compared with comparison subjects after adjusting for patients' geographic location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, and stroke. However, we failed to find a significant difference in the adjusted hazard of CHD during the 3-year follow-up period between prostate cancer patients who did and those who did not receive ADT (hazard ratio = 1.12, 95% CI = 0.79-1.59). We concluded that prostate cancer but not ADT was significantly associated with CHD. In addition, a common cause of prostate cancer and coronary heart disease could exist.

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder

“…The final study sample consisted of 1714 PC patients, 868 patients who received ADT, the study group, and 846 patients who did not receive ADT, the comparison group. These selection criteria are consistent with prior studies [16]. …”

“…This dataset is available to academic researchers in Taiwan to extract samples as needed. As illustrated by several publications [16–18], hundreds of studies using this dataset have been published in international peer-reviewed journals.…”

Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study

“…Our results are in agreement with previous Asian population-based studies, including the Japanese population [25] and the Taiwanese population [26]. The Japanese population study showed no increased risk of coronary heart disease in patients exposed to ADT.…”

Different network pharmacology mechanisms of Danshen-based Fangjis in the treatment of stable angina

“…For example, Wang et al reported that coronary heart disease could be treated through modulating adrenergic, angiotensin, calcitonin, and neurotensin receptors of the neuroactive ligand-receptor interaction pathway [55] . In a 3-year, follow-up study, Wang et al [56] found that the recurrence rate of coronary heart disease was higher in patients with both coronary heart disease and prostate cancer than that in patients with coronary heart disease alone, suggesting that the incidence of coronary heart disease was closely linked to prostate cancer. Moreover, there is evidence to suggest that factor H and complement C3, of the complement and coagulation cascades pathway, are associated with heart disease [57,58] .…”